key: cord-0954832-7k3d5ycf
authors: Hanna, Nazeeh; Hanna, Monica; Sharma, Surendra
title: Is Pregnancy an Immunological Contributor to Severe or Controlled COVID‐19 Disease?
date: 2020-08-05
journal: Am J Reprod Immunol
DOI: 10.1111/aji.13317
sha: edaee64df76490bdbb9509df9b79a54f27c1ca7d
doc_id: 954832
cord_uid: 7k3d5ycf

Since its emergence in Wuhan as a novel coronavirus disease, it has taken only a few months since January 2020 for it to be recognized as a wide spread COVID‐19 pandemic which has contributed to global health devastation. As pointed out by health experts, it is a once in a century pandemic of our times. Clinical observations so far indicate that the older population and immune compromised individuals, particularly in African American and Hispanic/Latino communities, are at much higher risk for infection with this novel coronavirus. In this regard, pregnancy offers an altered immunity scenario which may allow severe COVID‐19 disease. The literature is so far highly conflicting on this issue. This review will offer a conceptual basis for severe or controlled disease and address trepidations for pregnant women associated with COVID‐19 pandemic, particularly in the comparative context of clinical consequences of other coronaviruses such as SARS and MERS. We will highlight the possible consequences of COVID ‐19 on the general health of pregnant women as well as its possible effects at the maternal‐fetal interface. For the placenta‐related pathology, we will focus our discussion on the temporal expression of ACE2 throughout gestation for possible propagation of SARS‐CoV‐2 in the placenta in infected women and ensuing consequences.

It is for the first time in almost a century that the severity of COVID-19, combined with its pandemic spread, has placed unparalleled pressure on our healthcare system and global economy in a span of only a few months 1, 2 . This warrants that treatment strategies should be urgently available either in the form of an efficacious vaccine or a drug. A very recent press release from the University of Oxford in England puts dexamethasone, a common steroid, at the center of treatment modalities, which still needs to be validated for its efficacious use at least in severe COVID-19 cases.

Nevertheless, overall lack of a well-defined drug or vaccine leaves the global population at the mercy of social distancing, face covering, and almost complete avoidance of mass gatherings and travel.

Along with the older population and immune compromised individuals at much higher risk for infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3,4,5 , it was thought that pregnant women would also fall in the clinical category of severe COVID-19 cases 6.7,8 . This notion manifested from the known observations of altered immunity and hormonal influx during pregnancy 9, 10, 11 . However, data so far does not support significant detrimental effects of SARS-CoV-2 on the general health of pregnant women. On the other hand, the placenta expresses angiotensinconverting enzyme-related carboxypeptidase 2 (ACE2), a cognate receptor for SARS-CoV-2 12,13,14 ,

This article is protected by copyright. All rights reserved and presents itself as a possible site for infection. Since the maternal-fetal interface maintains antiinflammatory pregnancy-compatible immunity during gestation 9, 10, 11 , it was presumed that there will be an active propagation of the novel virus in the placenta. This scenario could change the highly choreographed cross-talk between the placenta and the maternal immune system that could impart vertical transmission of the virus and affect neonatal health, in particular the neurological development 15, 16 . Although it is too early in the pandemic to foretell long-term health consequences in children born to COVID-19-positive mothers, other clinical suppositions have not turned out to be on the serious side of the spectrum 17, 18 , and it may be related to anti-viral and/or anti-inflammation salient features of the maternal-fetal interface or temporal expression of ACE2. This review will provide insights to the question whether pregnancy is an immunological contributor to severe and controlled COVID-19 disease.

One major finding related to COVID-19 infection is that many patients remain asymptomatic 19, 20 and yet are fully capable of transmitting virus, suggesting that the virus is actively propagating in these individuals 21, 22 . It is possible that strong anti-COVID immune responses protect these individuals from developing severe disease. Appearance of symptoms of symptomatic dyspnea (shortness of breath) is seen, in most cases, almost a week after infection 21, 22 . This may provide a window of transmission in the absence of severe disease with acute respiratory distress syndrome (ARDS) triggered by a cytokine storm 23, 24 . Recent articles have provided a detailed overview of the innate and adaptive immune hyperactivity that may act as a double edged sword for combating the severe consequences of COVID-19 infection 25, 26, 27, 28 . For innate immune hyper-activation in response to COVID-19 infection, the focus has been placed on macrophages and neutrophils 25, 27, 28 . While data on COVID-19 patients continue to rapidly emerge, the research on innate immune dysfunction programmed by macrophages, neutrophils and other myeloid cells in SARS-CoV-1and MERS may provide some clues. One key finding is that pathogenic CoVs have mounted multifold strategies to escape immune detection. In particular, CoVs failed to elicit the type 1 interferon (IFN-1) immune response 29, 30 . This may also be the case with COVID-19 31 . This lack of response is not related to non-

This article is protected by copyright. All rights reserved engagement of pattern-recognition receptors (PRRs) and/or danger-associated molecular patterns (DAMPs). Pathogenic (sterile) inflammation in COVID-19 patients is most likely induced by activation of PRRs and DAMPS, culminating in production of cytokines such as IL-1β, IL-6 and IL-18 28, 32, 33, 34 . IL-1β and IL-6 can then promote recruitment of neutrophils and cytotoxic T cells 27, 32 .

Indeed, COVID-19 patients harbor an expanded population of circulating monocytes that secret IL-1β and IL-6. COVID-19 patients also show higher content of circulating lactate dehydrogenase (LDH) 33 , a marker of sterile inflammation (pyroptosis). These studies could be further strengthened by studying pyroptosis markers such as cleaved gasdermin D and caspase-1 35 . For neutrophil recruitment, an autopsy specimen from a patient who succumbed to COVID-19 showed extensive infiltration.

Neutrophil infiltration may give rise to formation of neutrophil extracellular traps (NETs) and to pneumonitis and/or ARDS-related mortality in COVID-19 patients 27, 36 .

It is evident that a single cytokine or dysregulated innate immunity cannot be assigned a sole pathological inducer in severe COVID-19 infections. For example, blocking of IL-6 receptor signaling by Tocilizumab has only given mixed results with even poor results in severely ill patients 37, 38 . It is possible that primary activation of macrophages and IL-6 production, unlike secondary production in the case of chimeric antigen receptor (CAR)-T cell therapy, is quite overwhelming and may overcome blockade and cause severe pathology 34, 39 . It is expected that IL-β and IL-6 production in COVID-19 patients should promote activation of adaptive immunity. The question that remains unanswered is uninhibited viral dissemination. As mentioned earlier, dysregulated IFN-type1 response may be associated with poor innate immune response to COVID-19.

Is T cell-mediated immune response intact in COVID-19 patients? Is an adaptive immune response hyper-activated or suppressed? Unlike HIN1influenza virus incubation period (24-48 h), the incubation time for COVID-19 is at least 5-7 days and it takes another few days for a patient to be admitted to the intensive care unit 21, 40 . It is then possible that T cell responses are curtailed as a result of possible T cell loss or exhaustion (PD-1-PD-1L expression) which may contribute to slow, subacute propagation of COVID-19. In patients with COVID-19, progressive lymphopenia has been noticed 33, 41, 42 , supporting the concept of poor T cell responses. These observations suggest that immune responses occur in a non-synchronized manner with production of innate cytokines with poor T cell responses in the general population and raise an important question of how these immune

This article is protected by copyright. All rights reserved responses are elicited in COVID-19 infected pregnant women in the context of specialized immunity at the maternal-fetal interface and production of pregnancy hormones.

Respiratory infections during pregnancy are associated with increased infectious morbidity and high maternal mortality rates 43 influenza infection during pregnancy. During the H1N1 influenza pandemic, pregnant women made up 5% of deaths, despite only making up 1% of the population and pregnancy risk of ICU admission was reported as high as a 7-fold increase 47, 48 . It was also demonstrated that pregnant patients with comorbidities such as obesity had increased risk for severe illness consistent with the general population with similar comorbidities 44 . These results suggest that the pregnancy immune alteration that was expected to cause detrimental effects on the general health of pregnant women with COVID-19 infection was somehow balanced unlike other respiratory illnesses during pregnancy.

This article is protected by copyright. All rights reserved Chen et al published a report from Wuhan covering the information on 118 SARS-CoV-2 infected pregnant women stating that the rate of severe maternal disease was 7.6% 49 . Some other studies have reported even lower prevalence of infection in pregnant women 50 . A study with severe disease rate was from New York City, presumably including African American and Hispanic patients 18 . These studies and others have not demonstrated that COVID-19 puts pregnant women at relatively much higher risk of complications than those seen in non-infected pregnant women. At this point, there is simply a precautionary warning from CDC and ACOG but solid information is not yet available.

Importantly, according to the CDC Morbidity and Mortality Weekly Report (MMWR), black non-Hispanic and white non-Hispanic pregnant women exhibit similar COVID-19 infection rates unlike in the general older population. On the other hand, Hispanic or Latino pregnant women show significantly higher infection rates with minimal severe disease. It is presumed that since women experience immunologic, hormonal and metabolic changes, these could increase their risk of severe illness from respiratory complications. However, this is simply a presumption and no solid information is available to support this notion. Moreover, extended incubation period and asymptomatic status of SARS-CoV-2 infection may make this virus behave differently than other coronaviruses.

Does the protective immunity at the maternal-fetal interface take advantage of asymptomatic period and is responsible for lack of the expected severe disease or vertical transmission in COVID-19 infected pregnant women? Besides placental immunity including anti-inflammatory cytokines and hormones, recent evidence also suggests that active trophoblast autophagy can induce resistance to viruses 51, 52, 53 . On the other hand, some viruses can exploit autophagy for their survival 54 . Whether the placenta mounts such a response against SARS-CoV-2 is not known. During normal pregnancy, antiinflammatory cytokines enrich the intrauterine milieu and the decidual immunity is pregnancycompatible involving M2 macrophages, regulatory T cells, non-cytotoxic NK cells, and tolerized T cells 9, 10 . In the case of SARS-CoV-2 infections, increased T-helper 2 (Th2) associated antiinflammatory cytokines are detected 21, 55 . This suggests that this novel virus does not dampen the pregnancy-associated anti-inflammatory milieu. We do not know whether COVID-19 infection has

This article is protected by copyright. All rights reserved any effect on placental hormone production. As discussed earlier, sterile inflammation (pyroptosis) dominated by IL-β and IL-6 has been thought to be induced during COVID-19 infection. It is possible that elevated Th2 responses during pregnancy blunt sterile inflammation and suppress the severity of the COVID-19 disease. A thorough study on hormone production, immune changes, and cytokine production is warranted to better understand the effect of SARS-CoV-2 infection in pregnant women.

Signature features of COVID-19-related severe illness include the presence of elevated levels of pro-inflammatory cytokines, coagulopathy, and lymphopenia 41, 42, 43, 56, 57 . Lymphopenia signifies severe reduction in lymphocytes and is used as a consistent predictor of COVID-19-associated mortality 33 . Pregnancy is intrinsically associated with moderate reduction in lymphocytes 58, 59 .

Although representing a small sample size, laboratory results did show marked lymphocyte decrease in 5 out of 9 women with pneumonia between 36 weeks and 39 weeks of pregnancy, suggesting that severe COVID-19 disease can further contribute to loss of lymphocytes 33 

This article is protected by copyright. All rights reserved

The CDC recently warned against an increased risk of preterm birth among pregnant people with COVID-19 44 . In a study that included women with COVID 19 infections in the second trimester, the pregnant women had higher rates of preterm birth due to preterm labor, PPROM, stillbirth, and fetal distress 61 . A recent study analyzed the clinical characteristics of symptomatic mothers with SARS-CoV-2 pneumonia (total 18 cases) in the third trimester (from 31 to 40 weeks gestation) 33 . Ten out of the eighteen pregnant women who were admitted before 37 weeks gestation delivered prematurely, suggesting an increased risk for preterm delivery with SARS-CoV-2 infection 15 .

At the NYU Winthrop Hospital, data were analyzed from a cohort of 155 COVID-19 positive mothers and their neonates'. There was no evidence of vertical transmission from mothers with SARS-CoV-2 infection to their newborns which agrees with the published observations. Forty-one percent of these mothers were asymptomatic but tested positive during universal screening upon admission. However, preterm delivery was significantly increased in symptomatic compared to asymptomatic mothers (p = 0.006) 62 .

As discussed earlier, there is growing recognition that cytokines play a pivotal role in the maintenance of a healthy pregnancy 63, 64 . A pro-inflammatory production of these immune modulators due to infections (bacterial/viral) can lead to pathologic pregnancy, including preterm labor, abortion, preeclampsia, and intrauterine growth restriction 65,66, . It is possible that the systemic pro-inflammatory cytokine storm often seen with severe SARS-CoV-2 infection will compromise the delicate balance of cytokines at the maternal-fetal interface inducing preterm births.

Another study described histopathologic findings in the placentas of women with COVID-19 infection 67 . Placental tissues from COVID-19 pregnancies showed an increased prevalence of decidual arteriopathy and other features of maternal vascular malperfusion. This pathology is often seen with placental injury reflecting oxygenation abnormalities and is associated with adverse perinatal outcomes. These changes may indicate complications related to placental viral infection, systemic inflammation (cytokine storm), maternal hypoxia or hypercoagulable state (Figure 1 ).

This article is protected by copyright. All rights reserved Vertical transmission from a mother to her fetus has not been observed in either SARS-CoV-1 or in MERS-CoV 68 . However, vertical transmission with COVID 19 remains to be clarified 69 increasing ANG 1-7 80 . ANG 1-7 is a bioactive peptide with vasodilatory activity and is thought to modulate the effect of the renin-angiotensin system on vascular tension 81, 82 . ACE2 also serves as the entry point into cells for some coronaviruses, including SARS-CoV-2 83, 84, 85 . Upregulation of ACE2 is likely to increase the susceptibility to SARS-CoV-2 infection 86, 87 .

Much of the focus has been on the kidney as the source of ACE2 during pregnancy, but data from the pregnant rat model suggest that the placenta and the uterus are important sources of ACE2 88, 89 , leading to an estimated twofold increase in total ACE2 activity during pregnancy 88 .

ACE2 deficiency can impact pregnancy by impairing gestational weight gain and restricting fetal growth in mice 90 .

These data are consistent with the hypothesis that transient ACE2 overexpression and increased activity during pregnancy may be important in modulating blood pressure during pregnancy as well as local hemodynamics in the uteroplacental unit 88, 89 . However, transient ACE2 overexpression may also indicate increased suitability to SARS-CoV-2 infection during pregnancy 88 .

Similar to the mouse model, the human placenta expresses ACE2 enzyme 91, 92, 93 . Therefore, it is likely that SARS-CoV-2 can infect the placenta and can lead to adverse pregnancy outcomes. In a study

This article is protected by copyright. All rights reserved using single-cell RNA sequencing, ACE2 was highly expressed in maternal-fetal interface cells including, cytotrophoblasts and syncytiotrophoblasts from first trimester samples 94 . This ACE2 expression was further increased at 24 weeks gestation. The high expression of ACE2 in these cells suggests that the placenta has the potential to be infected by SARS-CoV-2 and may cause placental dysfunction and pregnancy complications. However, there were no scRNA-seq data from human placentas in the third trimester 94 .

Recently our laboratory evaluated ACE2 expression in the human placenta in a gestational age-dependent manner. Total placental RNA from the first and second trimester terminations as well as from term delivery (before the onset of labor) was isolated and ACE2 expression was determined by SYBR Green Primer assay. Our results suggest significant expression of ACE2 in the first and second trimester placental samples that was found to be somewhat decreased in term placenta (6 samples per group, P<0.05, by One-way ANOVA followed by Kruskal Wallis test). The ACE2 expression was localized to cytotrophoblasts and syncytiotrophoblasts in first and second trimester placental tissues as visualized by immunohistochemistry.

Taken together, we hypothesize that placental trophoblasts may be susceptible to infection by SARS-CoV-2 infection in early/mid pregnancy but not that robustly at term due to the differential expression of ACE2 throughout gestation (Figure 1) . On the other hand, ACE2 expression may be optimal in most reproductive tissues during labor. However, it is possible that term placenta in labor or otherwise presents a variant form of ACE2 incapable of functioning as a receptor for SARS-CoV-2. This can explain the rarity of placental infection/vertical transmission observed at term pregnancy.

Furthermore, it might explain observed pregnancy complications in mid pregnancy, including preterm birth, abruption, and stillbirth. However, a solid experimental and clinical support for our hypothesis is still awaited.

Discussion on COVID-19 infection and its consequences changes on daily basis with new insights for general population. For example, it was previously thought that only older population and immune compromised individuals were at risk for severe disease. However, recent data suggests that Accepted Article younger populations including children can be infected and develop severe complications. The fluid situation with COVID-19 further complicates the maternal and fetal clinical care and the management of healthy pregnancy. It is clear that being current with the emerging new data regarding the extent of the disease and treatment modalities is vital, particularly for pregnant women. On a semi-positive note, it appears that pregnant women have not presented with the expected high rate of mortality and severity of the disease as compared to their non-pregnant women. We still do not have clarification on whether African American and Hispanic women are at higher risk of developing severe COVID-19 disease. CDC and ACOG have published directives for pregnant women that they may be at higher risk of severe disease, although several reports suggest that pregnant women may remain asymptomatic. This review has attempted to address the question whether pregnancy is an immunological contributor to severe or controlled COVID-19 disease. We propose that the placenta, fetal membranes, and pregnancy intrauterine milieu may provide a protective environment to SARS-CoV-2 infection and suggest that therapeutic interventions should also include cues from the maternal-fetal interface tissues. We further propose that based on temporal ACE2 expression, COVID-19 placental infection may occur during first and second trimester with little or no infection during third trimester. This may also explain, in part, the poor vertical transmission of this novel virus at term pregnancy but the possible increased incidence of preterm births in mid pregnancy. We also support the precautionary notion that pregnancy may provide an immunological balance to COVID-19-mediated alterations at the maternal-fetal interface.

WHO. Rolling updates on coronavirus disease (COVID-19). Available from URL

WHO Coronavirus Disease (COVID-19) Dashboard

Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States

COVID-19 and African Americans

Covid-19 and Immunity in aging populations-Anew research agenda

Coronavirus disease 2019 (COVID-19) and pregnancy: Responding to a rapidly evolving situation

Clinical Characteristics of pregnant women with Covid-19 in Wuhan

No SARS-CoV-2 detected in amniotic fluid in mid pregnancy

Natural killer cells and regulatory T cells in early pregnancy loss

Immunology of the maternal-fetal interface

Immune responses at the maternal-fetal interface

Accepted Article This article is protected by copyright. All rights reserved 13

The SRARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study

Why are pregnant women susceptible to COVID-19: An Immunological viewpoint

COVID-19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcome

COVID-19 and pregnancy: a review of current knowledge

Characteristics and outcome of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at five New York City Medical Centers

Presumed asymptomatic carrier Transmission of COVID-19

Transmission 2019-nCoV infection from an asymptomatic contact in Germany

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

China Medical Treatment Expert Group for cOVID-19. Clinical Characteristics of coronavirus disease 2019in China

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Covid -19 in criticall ill patients in the Seattle region -Case series

The many facets of the anti-COVID immune response

The Sinai Immunology Review Project. Immunology of COVID-19: Current state of the science

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Deep immune profiling of COVID-19 patients reveal distinct immunotypes with therapeutic implications

Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection model

The SARS coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-dependent downregulation of the type 1 interferon receptor

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Accepted Article This article is protected by copyright. All rights reserved

Immune cell profiling of COVID-19 patients in the recovery stage by single cell sequencing

Clinical and Immunological features of severe and moderate coronavirus disease 2019

COVID-19: Consider cytokine storm syndromes and immunosuppression

Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors

Vander Heide RS. Pulmonary and cardiac pathology in African American Patients with COVID-19: an autopsy series from New Orleans

Tocilizumab treatment in COVID-19: A single center experience

Effective treatment of severe COVID-19 patients with tocilizumab

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19

Lymphopenia predicts disease severity of COVID-19. A descriptive and predictive study

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: Asystemic review and meta-analysis

Observations on excess mortality associated with epidemic influenza

Effects of influenza on pregnant women and infants

The Centers for Disease Control and Prevention's maternal health response to 2009 H1N1 influenza

Clinical Characteristics of pregnant women with COVID-19 in Wuhan, China

Universal SARS-CoV-2 testing on admission to labor and delivery: Low prevalence among asymptomatic obstetric patients

Autophagy as a mechanism of antiviral defense at the maternal-fetal interface

Accepted Article This article is protected by copyright. All rights reserved

Human trophoblasts confer resistance to viruses implicated in perinatal infection

ATG16L1 governs placental infection risk and preterm birth in mice and women

Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice

The pathogenesis and treatment of the cytokine storm in COVID-19

Cytokine release syndrome in severe COVID-19: interleukin 6 receptor antagonist tocilizmab may be the key to reduce mortality

Coagulopathy of coronavirus disease 2019

Suppression of B lymphopoiesis during normal pregnancy

Effect of pregnancy on thymic T cell development

COVID-19 infection among asymptomatic and symptomatic pregnant women. Two weeks of confirmed presentations to an affiliated pair of New York City hospitals

Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy

Accepted Article This article is protected by copyright. All rights reserved

Outcome of Maternal-Newborn Dyads after Maternal SARS-CoV-2 during Pregnancy MS ID#

Gestational Age dependent Expression of Interleukin-10 and its receptor in Human Placental Tissues and isolated Cytotrophoblasts

Infection and prematurity and the role of preventive strategies

Is midtrimester short cervix a sign of intraamniotic inflammation?

Placental Pathology in COVID-19

Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know

Perinatal aspects on the covid-19 pandemic: a practical resource for perinatal-neonatal specialists

Accepted Article This article is protected by copyright. All rights reserved

Detection of SARS-COV-2 in Placental and Fetal Membrane Samples

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province

Vertical Transmission of Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A Review

Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection

SARS-CoV-2 infection of the placenta

Visualization of SARS-CoV-2 virus invading the human placenta using electron microscopy

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Accepted Article This article is protected by copyright. All rights reserved

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications

Angiotensin-converting enzyme 2 as a therapeutic target for heart failure

Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2

Cardiac angiotensin-(1-7) in ischemic cardiomyopathy

The secret life of ACE2 as a receptor for the SARS virus

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome

ACE2 expression and activity are enhanced during pregnancy

ACE2 and ANG-(1-7) in the rat uterus during early and late gestation

Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction

Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies

Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with intrauterine growth restriction

Materno-fetal transmission of human coronaviruses: a prospective pilot study

The SARS-CoV-2 receptor ACE2 expression of maternal